I mmune checkpoint inhibitors, which enhance antitumor immune response, [1] [2] [3] are associated with atypical response patterns 4 ,5 that may not be fully captured by conventional response criteria such as Response Evaluation Criteria in Solid Tumors (RECIST). 6 These atypical response patterns include responses following an apparent increase in tumor burden ("pseudoprogression") and responses in the presence of new lesions. In advanced melanoma, immunerelated responses have been observed in approximately 10% of patients treated with ipilimumab (anti-cytotoxic T-lymphocyte antigen 4), 5 and in approximately 7% to 9% of patients treated with nivolumab or pembrolizumab (antiprogrammed cell death receptor 1 [anti-PD-1]). [7] [8] [9] Nivolumab is a fully human monoclonal IgG4 antibody that selectively blocks the interaction between PD-1 on activated T cells and its ligands, programmed cell death ligands 1 (PD-L1) and 2 (PD-L2), on tumor cells as well as tumor-infiltrating immune cells. [10] [11] [12] [13] Based on phase 3 trial data showing improved overall survival (OS) and progression-free survival (PFS) compared with dacarbazine (CheckMate 066) 7 and improved PFS and objective response rate vs ipilimumab (CheckMate 067), 14 nivolumab monotherapy was approved for the treatment of advanced melanoma in many countries around the world. In CheckMate 066, treatment-naive patients with BRAF wild-type melanoma treated with nivolumab had an improved OS compared with those who received dacarbazine (prepared as a citrate salt) (hazard ratio for death, 0.42; 99.8% CI, 0.25-0.73; P < .001). Whereas the objective response rate with nivolumab was high (40%), approximately 30% of patients experienced a best overall response of progressive disease. 7 Similarly, in CheckMate 067, the median PFS was significantly longer for patients who received nivolumab plus ipilimumab (11.5 months; 95% CI, 8.9-16.7 months) or nivolumab monotherapy (6.9 months; 95% CI, 4.3-9.5 months) compared with ipilimumab monotherapy (2.9 months; 95% CI, 2.8-3.4 months; P < .001 for both comparisons). 14 Progressive disease was reported in 23%, 38%, and 49% of patients treated with the combination, nivolumab monotherapy, and ipilimumab monotherapy, respectively. Although disease progression is considered failure of treatment for nonimmunotherapeutic agents, resulting in treatment discontinuation, the possibility of delayed, immune-related responses suggests that patients with disease progression could benefit from continued treatment with immune checkpoint inhibitors. Therefore, across the nivolumab development program, patients were permitted to continue study treatment after initial investigator-assessed RECIST v1.1-defined progression, provided that they were considered to be deriving clinical benefit and tolerating the study drug. The objective of this retrospective analysis was to evaluate the safety and potential benefit of nivolumab monotherapy beyond the first RECIST v1.1-defined progression in patients with advanced melanoma.
Methods

Study Design and Treatment
This analysis pooled data from patients treated with nivolumab monotherapy in CheckMate 066 (n = 206) 7 or CheckMate 067 (n = 313) ( Figure 1 ). 14 Patients received nivolumab, 3 mg/kg, every 2 weeks by intravenous infusion until disease progression by RECIST v1.1 criteria 6 or unacceptable toxic effects. The protocols for CheckMate 066 and CheckMate 067 state that patients could be treated beyond first progression provided that they exhibited investigator-assessed clinical benefit without substantial adverse effects related to nivolumab. Assessment of clinical benefit took into account whether the patient was clinically deteriorating and unlikely to receive further benefit from continued treatment. Investigators selected patients for TBP after consultation with and approval from the study monitors. In this analysis, patients treated beyond first disease progression were defined as those who received their last dose of nivolumab more than 6 weeks after progression (TBP group). A subgroup of these patients that had greater than 30% tumor reduction in target lesion after progression when compared with baseline was evaluated separately (TBP>30% group). Patients not treated beyond progression discontinued nivolumab before or at RECIST-defined progression (non-TBP group).
Patients
Eligible patients had histologically confirmed unresectable stage III or IV malignant melanoma and had received no prior systemic therapy for advanced disease. 7, 14 Patients were at least 18 years of age, with measurable disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients with active brain metastases, ocular melanoma, or autoimmune disease were excluded from both studies. In CheckMate 066, all patients had BRAF wild-type melanoma; in CheckMate 067, patients with BRAF wild-type or BRAF-mutated melanoma were eligible. 7, 14 All patients provided written informed consent. The protocols were approved by either the relevant institutional review boards or ethics committees at each investigator's study site. The studies were conducted in accordance with the Declaration of Helsinki with good clinical practice as defined by the International Conference on Harmonisation.
RECIST progression, or death. Overall survival was defined as time from randomization to death. Tumor assessments included objective response rate based on investigatorassessed RECIST v1.1 criteria, time to response, and duration of response, defined as time from complete or partial response to first disease progression. Tumors were assessed at baseline, every 6 weeks from randomization for the first year, and every 12 weeks thereafter, until disease progression or treatment discontinuation, whichever occurred later. After treatment discontinuation, patients were evaluated every 3 months for survival and safety. Adverse events (AEs) were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. Select AEs, defined as those with a potential immunologic cause, were analyzed by organ category.
Statistical Analyses
Objective response rate was defined as the number of patients with a best overall response of complete or partial response divided by the number of randomized patients for each 306 Analyzed with RECIST-defined progression
Patients were assessed for eligibility and randomized in 2 separate phase 3 trials, CheckMate 066 and CheckMate 067. 7, 14 Other treatments (in addition to nivolumab monotherapy) to which patients were randomized comprised dacarbazine (n = 208) in CheckMate 066 and nivolumab plus ipilimumab (n = 314) or ipilimumab monotherapy (n = 315) in CheckMate 067. TBP indicates treatment beyond progression.
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Original Investigation Research jamaoncology.com (Reprinted) JAMA Oncology November 2017 Volume 3, Number 11 1513 group, with 2-sided, 95% CIs for the response rate based on the Clopper-Pearson method. Progression-free survival and OS were estimated using Kaplan-Meier methodology; 2-sided, 95% CIs for median PFS and OS were computed by the Brookmeyer and Crowley method. Tumor burden change (sum of diameters of target lesions) over time for each patient was displayed graphically.
Results
Patient Characteristics at Baseline and Progression
Median time from randomization to last known date alive or death in the TBP, non-TBP, and TBP>30% groups was 14.3 (range, 5.0-27.9), 9.9 (range, 0.3-27.6), and 15.0 (range, 10.4-24.7) months, respectively. Of 526 patients allocated to nivolumab monotherapy, 306 (58%) experienced disease progression; 85 (28%) patients with progressing disease were in the TBP group and 221 (72%) were in the non-TBP group (eTable 1intheSupplement; Figure 1 ). The remaining 220 (42%) patients did not experience disease progression with nivolumab ( Figure 1 ). Among the 85 TBP patients, 30 were from CheckMate 066 and 55 were from CheckMate 067. Twentyfour TBP patients (28%) had a target lesion reduction of greater than 30% after progression when compared with baseline (eTable 1 in the Supplement; Figure 1 ). Formal hypothesis testing was not conducted; however, numerical differences were noted between TBP and non-TBP patients. Relative to non-TBP patients, TBP patients were more likely to have a baseline ECOG performance status of 0 Table 1 ). None of the TBP>30% patients had LDH levels above the ULN at progression and 20 (83%) had an ECOG performance status of 0. The median change in tumor volume (size in target lesions as per RECIST v1.1 criteria) at progression was an increase of 15% (range, −100% to 353%) in non-TBP patients and a decrease of 9% (range, −100% to 176%) and 45% (range, −87% to 64%) in TBP and TBP>30% patients, respectively. In TBP patients, progression in many cases was due to the appearance of new lesions despite a decrease in target lesions (Table 1) .
Response Before First Progression and Time to Progression
In the period from the start of nivolumab treatment to first disease progression, non-TBP and TBP groups had a similar objective response rate (Figures 2 and 3) . 
Duration of Treatment and Survival
In the TBP group, 65 patients (76%) were alive and 27 (32%) were continuing treatment at the time of the analysis (Figure 2 ). In the TBP>30% group, 21 patients (87%) were alive and 11 (46%) were continuing treatment ( Figure 2 ). The median number of nivolumab doses received after progression was 9.0 (range, 3-53) for the TBP group overall and 16.5 (range, 5-41) for the TBP>30% group. The median time from progression to last dose of study treatment was 4.7 months (range, 1.4-25.8 months) for TBP patients and 7.6 months (range, 2.4-19.4 months) for TBP>30% patients. The median time from progression to greater than 30% tumor reduction compared with baseline was 1.4 months (range, 0.2-7.0 months) in TBP>30% patients. Of the 85 TBP patients, 36 (42%) had a reduction in tumor burden after first progression (eFigure 1 in the Supplement). The TBP patients who achieved subsequent tumor reduction after initial disease progression did so before week 24 ( Figure 3 ). Median OS from randomization to nivolumab treatment was not reached (95% CI, 21.5 to not reached) for TBP patients and was 10.6 months (95% CI, 8.1-14.2 months) for non-TBP patients, with 24-month OS rates of 59% (95% CI, 36%-76%) and 25% (95% CI, 16%-35%), respectively (eFigure 2 in the Supplement). 
Overall Safety
Any-grade, treatment-related select AEs were similar, but generally occurred more frequently, in the TBP group than in the non-TBP group ( 
Discussion
This retrospective, pooled analysis of data from the phase 3 studies CheckMate 066 and CheckMate 067 suggests that a proportion of patients with treatment-naive advanced melanoma who receive nivolumab beyond RECIST v1.1-defined progression may derive apparent clinical benefit. Although the data in this report are still immature, given the lack of OS data from CheckMate 067, 76% of patients treated with nivolumab beyond first progression were alive at the time of this analysis, while 32% continued to receive treatment. We also identified differences in OS between TBP and non-TBP patients (24-month OS rate, 59% and 25%, respectively). The safety profile associated with TBP was similar to that reported in a large pooled analysis of data from 576 patients who received nivolumab monotherapy. 15 Patients who continued nivolumab therapy were less likely than non-TBP patients to require any subsequent cancer therapy and were more likely to have surgery, which could suggest that nivolumab TBP resulted in tumor shrinkage that allowed for surgical resection or that progression was isolated and not reflective of the total tumor burden. Atypical response patterns have been noted in patients treated with nivolumab beyond RECIST-defined progression in melanoma, 7, 16 non-small-cell lung cancer, 17 and renal cell carcinoma. 18, 19 They have also been observed with use of other immune checkpoint inhibitors, 8, 9, 20, 21 although it is worth noting that we found delayed response to be rare after 24 weeks in patients treated beyond progression. Immune-related response criteria (irRC) were proposed to enable more appropriate monitoring of response in patients receiving immunotherapy. These criteria base antitumor (14) 2 (1) 18 (21) 1 (1) Diarrhea 31 (14) 2 (1) 18 (21) 1 ( b These data were not adjusted for differences in treatment exposure.
response on total measurable tumor burden, so that the appearance of new lesions, for example, would not necessarily represent progressive disease if accompanied by an overall reduction in burden of all measurable lesions. To date, trials of immune checkpoint inhibitors have not consistently reported response rates based on the irRC, and rigorous comparison of clinical outcomes using RECIST and irRC has not been made. Although irRC are not likely to be widely used in clinical practice, they have helped to raise awareness of atypical response patterns with immune checkpoint inhibitors and that stopping treatment at first signs of apparent tumor progression may be inappropriate in a patient who is otherwise tolerating treatment well. For example, ipilimumab treatment may result in delayed onset of effect, and some patients who initially responded or had stable disease with ipilimumab, but later experienced disease progression, achieved further disease control on ipilimumab retreatment.
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In our analysis, 24 patients had greater than 30% tumor reduction in target lesion after progression when compared with baseline, representing approximately 5% of all patients allocated to nivolumab monotherapy (N = 526), which is consistent with known estimates of atypical immune-related response patterns observed in other anti-PD-1 studies (approximately 7%-9%). [7] [8] [9] Two main hypotheses have been proposed to account for the apparent disease progression ("pseudoprogression") that sometimes precedes responses in patients treated with immune checkpoint inhibitors. 5 First, patients with relatively high immune suppression within the tumor microenvironment may have a comparatively slow antitumor immune response that is ultimately sufficient to reduce tumor burden, allowing for continued tumor growth of target lesions or the appearance of new lesions in the interim. Alternatively, treatment may induce a transient immune cell infiltration into the tumor, accompanied by edema, giving the appearance of increased tumor burden on imaging. This type of inflammatory reaction has been confirmed by biopsy in patients treated with ipilimumab 5, 23, 24 and in patients treated with anti-PD-1 combination therapy. 25 Because disease progression is defined by RECIST as a 20% or more increase in tumor target lesion size or the appearance of new lesions, an inflammatory reaction with immune checkpoint therapy may be mistaken for disease progression, leading to treatment discontinuation before realization of treatment benefits.
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Two retrospective analyses of the efficacy and safety of nivolumab in patients with renal cell carcinoma treated beyond progression 18, 19 suggested that continued nivolumab treatment benefited a proportion of patients in terms of tumor reduction, as well as longer median OS compared with patients not treated beyond progression, with no new or unexpected AEs observed. A third analysis of the same phase 3 data by the US Food and Drug Administration defined TBP differently, 27 thus resulting in a lower number of patients with progressive disease followed by a decrease of at least 30% in tumor after continued treatment with nivolumab. Nevertheless, similar to our findings, the investigators' decision to treat with nivolumab beyond progression may have been based in part on patient characteristics, such that patients with poor clinical characteristics were unlikely to receive continued treatment. In our analysis, patients who had, for example, LDH level greater than ULN at progression, or an increase in target lesions and appearance of new lesions at progression together, were less likely than those without these characteristics to be treated beyond progression. Similarly, in the aforementioned renal cell carcinoma analysis, patients with high incidence of new bone lesions and low quality of life scores were less likely than those without these characteristics to be considered for continued nivolumab treatment. 18, 19 Additional evaluation of factors influencing the decision to continue treatment beyond progression (eg, lack of other alternatives at the time of the decision) may help investigators to identify appropriate candidates for this approach.
Limitations
Although our analysis provides insights into the extended use of nivolumab beyond disease progression, interpretation of these results is limited by several factors, including the use of retrospective data, the relatively small number of patients treated beyond disease progression, and selection of patients for extended treatment by investigators based on factors that have not been systematically explored. In the absence of randomized data, it is unclear that these patients would not have survived as long without being exposed to further nivolumab treatment. Future studies should examine outcomes among patients treated beyond disease progression in large, prospective cohorts that are randomized on progression to further treatment or to observation only. Randomized trials would also allow for better assessment of the safety of continued treatment compared with alternative care on progression. Although no new or unexpected AEs were observed in patients treated beyond progression in our analysis, continued treatment may be associated with risks, as observed in renal cell carcinoma.
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Conclusions
In summary, our analysis shows that patients treated beyond their first disease progression can experience a tumor response with continued nivolumab treatment, with a safety profile consistent with that observed in patients who did not receive further treatment. Although patients selected for continued treatment were typically healthier than those who were not selected, it is possible that patients with less favorable clinical characteristics would have also benefited from further nivolumab therapy after progression. The results of this analysis suggest that continued treatment with nivolumab may be an option to achieve further apparent clinical benefit in some patients with advanced melanoma. 
